Login / Register
News & Articles

The latest news and features from around the world.  A one stop resource for the most up to date renal and urology news. Why not discuss some of these news stories in our forum?

Kidney Cancer News elsewhere on the Web

20: Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518) – PMC

20: Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518) – PMC

By Nazli Dizman, Rebecca S Slack-Tidwell, Rahul A Sheth, Omar Alhalabi, Matthew T Campbell, Paul G Corn, Sangeeta Goswami, Andrew Johns, Eric Jonasch, John K Lin, Amishi Y Shah, Jianbo Wang, Amado J Zurita-Saavedra, Jianjun Gao, Nizar Tannir, Andrew W Hahn & Pavlos Msaouel | 10 October 2025 | Articles, Around the Web
20: Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY ...
2: Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141) – PMC

2: Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141) – PMC

By Toni Choueri, Moshe Ornstein, Pedro C Barata, Marc Matrana, Jaime Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Chris Negro, Jianfen Chen, Paul Foster, Deepti Warad, Bradley A McGregor, Sun Young Rha & Alexandra Drakaki | 10 October 2025 | Articles, Around the Web
Hypoxia-inducible factor 2-alpha (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expression of ...
65: Treatment patterns and attrition rates for metastatic Non-Clear cell renal cell carcinoma in the US – PMC

65: Treatment patterns and attrition rates for metastatic Non-Clear cell renal cell carcinoma in the US – PMC

By Zeynep Irem Ozay, Yeonjung Jo, Hage Chadi Micah Chehade, Georges Ostrowski, Nicolas Gebrael, Ayana Sayegh, Richard Srivastava, Diya Ji, Tanner Garg, Edwin Hardy, Neeraj Lin, Benjamin Agarwal, Haoran Maughan, Umang Li & Swami | 10 October 2025 | Articles, Around the Web
Non-clear cell renal cell carcinoma (nccRCC) represents 25% of subtypes of kidney cancer and portends a poor prognosis [PMID: 37823185].
15: Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials – PMC

15: Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials – PMC

By Miguel Zugman, Jennifer R Rider, Nazli Dizman, Salvador Jaime-Casas, Vitor Abreu Goes, Koral Shah, Daniela V Castro, Benjamin Mercier, Peter Zang, Hedyeh Ebrahimi, Regina Barragan-Carrillo, Diwyanshu Sahu, Prithviraj Vikramsinh Mandora, JoAnn Hsu, Wesley Yip, Charles B Nguyen, Alex Chehrazi-Raffle, Robert Miller, Thomas Powles, Toni Choueiri & Sumanta K Pal | 10 October 2025 | Articles, Around the Web
Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC subtype, yet prospective evidence guiding first-line systemic therapy ...
1: Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study – PMC

1: Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study – PMC

By Laurence Albiges, Howard Gurney, Jae Lyun Lee, Vagif Atduev, Cristina Suarez, Miguel A Climent, David Pook, Piotr Tomczak, Philippe Barthelemy, Craig Gedye, Louis Lacombe, Thomas Ferguson, Viktor Stus, Pawel Wiechno, Mustafa Erman, Yuksel Urun, Jerry Cornell, Joe Burgents, Manish Sharma & Martin Voss | 10 October 2025 | Articles, Around the Web
First-line pembrolizumab plus lenvatinib showed durable responses in participants with advanced non–clear cell renal cell carcinoma (nccRCC) in ...
12: Evaluating global disparities in clinical trial availability for renal cell carcinoma – PMC

12: Evaluating global disparities in clinical trial availability for renal cell carcinoma – PMC

By Ruchi Agarwal, Jaya Goud, Miguel Zugman, Daniela Castro, Xiaochen Li, Koral Shah, Lily Lau, Aaron Lee, Salvador Jaime-Casas, Hedyeh Ebrahimi, Gabriela Regalado-Porras, Sharon Choi, Nora Sobrevilla-Moreno, Erika Ruiz-Garcia, Shivanee Kooner, Skylar Reid, Nasr Chaudhary, Rana McKay, Sumanta Pal & Regina Barragan-Carrillo | 10 October 2025 | Articles, Around the Web
Clinical trials are the cornerstone for generating high-quality evidence to improve patient outcomes. In metastatic renal cell carcinoma (RCC), ...
Development and evaluation of deep neural networks for the classification of subtypes of renal cell carcinoma from kidney histopathology images

Development and evaluation of deep neural networks for the classification of subtypes of renal cell carcinoma from kidney histopathology images

By Eliazer, M., Kumar, Guntupalli Manoj, Amaran, Sibi, Shasikala, Y., Sahu, Monalisa, Dash, Bibhuti Bhusan & Bala, Kanchan | 9 October 2025 | Articles, Around the Web
Renal cell carcinoma (RCC) is one of the typical categories of kidney cancer and is a varied group of malignancies arising from epithelial cells of the kidney parenchyma. RCC has more than ten subtypes. Classification of RCC sub-types is mainly according to morphologic features seen on ...
A novel dataset and efficient deep learning framework for automated grading of renal cell carcinoma from kidney histopathology images

A novel dataset and efficient deep learning framework for automated grading of renal cell carcinoma from kidney histopathology images

By Bamaqa, Amna & Alahamade, Wedad O. | 9 October 2025 | Articles, Around the Web
Kidney cancer, specifically renal cell carcinoma (RCC), represents a major global health issue, with increasing incidence rates, highlighting the necessity for effective and accurate diagnostic systems. Traditional methods for RCC grading, such as manual histopathological analysis, are labor ...
No results found.

Articles from Kidney Cancer UK

No results found.
No results found.
All Articles from Kidney Cancer UK